AKAO - Achaogen, Inc.

Achaogen, Inc. (AKAO) was a publicly traded biopharmaceutical company that focused on the development and commercialization of antibiotics to treat serious bacterial infections. The company was headquartered in South San Francisco, California, and was founded in 2002.

One of AKAO's main products was plazomicin, which was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of complicated urinary tract infections and bloodstream infections caused by certain bacteria. The company also had a number of other product candidates in its pipeline, including antibiotics for the treatment of multi-drug resistant infections.

However, in April 2019, AKAO filed for bankruptcy and announced that it would be ceasing operations. The bankruptcy was the result of the company's inability to secure additional financing to continue its operations. As a result, AKAO's stock is no longer traded on any stock exchange.

Investors who held AKAO stock prior to the bankruptcy may have been able to recover some of their investment through the bankruptcy proceedings, but the amount and timing of any potential recovery would depend on a variety of factors.